Risk of higher procurement costs from supply restrictions on generic drugs
First written in FY2024-Q1. 2 of 3 entries say "Materialised", first in FY2024-Q2. Latest entry: FY2024-Q3.
Hyuga Primary Care moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Materialised".
- FY2024-Q3MaterialisedAnnual report
「In addition, the supply of coronavirus treatments expanded in earnest from the previous fiscal year. Despite the transition of COVID-19 to a Category V infectious disease, our company continues to serve many elderly patients at high risk of severe illness. Accordingly, during the cumulative third quarter, the use of coronavirus treatments with low drug price margins continued to increase, and supply restrictions on generic drugs continued. As a result, the sales mix shifted toward drugs with lower drug price margins, and the pharmaceutical procurement cost ratio remained elevated during the cumulative third quarter, at approximately 2.0% above the level in the same period of the previous year.」
The increase in coronavirus treatments and supply restrictions on generic drugs continued, leaving the pharmaceutical procurement cost ratio approximately 2.0% above the level in the same period of the previous year. Prescription volumes remained high even after patients began paying part of the costs themselves from October onward, and the recovery has been delayed. - FY2024-Q2MaterialisedAnnual report
「In addition, the supply of coronavirus treatments expanded in earnest from the previous fiscal year. Despite the transition of COVID-19 to a Category V infectious disease, our company continues to serve many elderly patients at high risk of severe illness. Accordingly, during the cumulative second quarter, the use of coronavirus treatments with low drug price margins continued to increase, and supply restrictions on generic drugs continued. As a result, the sales mix shifted toward drugs with lower drug price margins, and the pharmaceutical procurement cost ratio remained elevated during the cumulative second quarter, at approximately 3% above the level in the same period of the previous year.」
The increase in coronavirus treatments and supply restrictions on generic drugs have continued, keeping the pharmaceutical procurement cost ratio approximately 3% above the level in the same period of the previous year. From October 2023 onward, the company expects prescription volumes to decline and the cost ratio to improve as patients begin paying part of the treatment costs themselves. - FY2024-Q1First statedAnnual report
「Supply restrictions on generic drugs have occurred, and it remains difficult to handle some products with high drug price margins. As a result, the sales mix has shifted toward drugs with lower drug price margins, and the procurement cost ratio for pharmaceuticals remained elevated during the cumulative first quarter, at approximately 3% above the level in the same period of the previous year.」
Actual supply restrictions on generic drugs have made it difficult to handle products with high drug price margins and have led to an approximately 3% year-on-year increase in the pharmaceutical procurement cost ratio.